PHARE: One-Year Trastuzumab Remains Standard for HER2-Positive Breast Cancer

Article

A 6-month regimen of treatment with trastuzumab for HER2-positive breast cancer failed to show noninferiority with the standard 12-month treatment regimen after 3.5 years of follow-up in the open-label, randomized, phase III PHARE trial.

A 6-month regimen of treatment with trastuzumab for HER2-positive breast cancer failed to show noninferiority with the standard 12-month treatment regimen after 3.5 years of follow-up in the open-label, randomized, phase III PHARE trial. Despite the increased rate of cardiac events that occurred in patients assigned to 12-months of treatment, the researchers concluded that the longer regimen should remain the standard of care.

Bottle of trastuzumab; source: Roche

The optimal duration of trastuzumab has been debated since the drug was first identified as having a benefit in patients with HER2-positive breast cancer. The HERA trial recently confirmed that a 2-year regimen of trastuzumab conferred no additional benefit when compared with a 1-year regimen. The PHARE trial was designed to compare a shorter 6-month regimen to the standard 12-month regimen; results of the trial were published recently in Lancet Oncology.

The PHARE trial included women aged 18 years or older with confirmed HER2-positive breast cancer who had been treated with at least 4 cycles of prior chemotherapy and had breast-axillary surgery before randomization. The researchers enrolled patients from 156 centers in France. Patients who had undergone 6 months of trastuzumab were randomly assigned to another 6 months of treatment (n = 1,691) or to discontinuation of treatment (n = 1,693). The intention-to-treat analyses included 1,690 patients from each group.

“Commonly, a per-protocol analysis is recommended for noninferiority trials, however, an intention-to-treat analysis was chosen for our analysis,” the researchers wrote. “This choice was based on the particular design of PHARE, in which patients were scheduled to be randomized after 6 months of trastuzumab treatment to either continuation for another 6 months or to discontinue.”

After 3.5 years of follow-up, 175 disease-free survival events occurred in patients assigned to 12 months of trastuzumab compared with 219 events in the 6-month group. Data indicated that the 2-year disease-free survival was 93.8% for patients assigned the standard of care compared with 91.1% for the 6-month regimen (HR = 1.28; 95% CI, 1.01–1.56; P = .29).

A greater percentage of patients assigned to 12 months of treatment experienced cardiac events compared with patients assigned 6 months of treatment (5.7% of patients vs 1.9%; P < .0001).

The researchers also analyzed the data according to subgroups of patients. Estrogen receptor–negative patients were found to have significantly shorter disease-free survival when assigned to the 6-month regimen. No difference was found between length of treatment when the researchers looked at the results according to other combinations of trastuzumab and chemotherapy and estrogen-receptor status.

The researchers cautioned that results of the subgroup analyses should be interpreted with caution and added that “longer follow-up is needed to reach a conclusion regarding noninferiority of 6 months of treatment to 12 months of treatment with trastuzumab in any of the subgroups, since the trial was not powered to answer these questions.”

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content